mri

Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections.

AMRI-59 is a potent inhibitor of [PrxI] possessing anti-tumor activity.

Amrinone (Inocor) is a positive inotropic cardiotonic (cardiotonic agent) with vasodilator properties, phosphodiesterase 3 inhibitory activity.

MMRi64 is a specific inhibitor of Mdm2-MdmX E3 ligase activity.MMRi64 potently induces p53 accumulation and apoptosis in the p53 pathway in leukemia lymphoma cells, disrupts Mdm2-MdmX interactions, and downregulates Mdm2 and MdmX in leukemia cells.MMRi64 MMRi64 can be used in cancer research.

MRIA9, an ATP-competitive inhibitor targeting pan Salt-Inducible Kinases (SIK) and PAK2 3, demonstrates IC50 values of 516 nM, 180 nM, and 127 nM for SIK1, SIK2, and SIK3, respectively [1].

MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol), a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12.

Inamrinone lactate is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.

Tamrintamab (SC-003 mAb) is an antibody targeting dipeptidase 3 (DPEP3), a potential cytotoxic agent for ovarian cancer research.

α-Conotoxin MrIC is a biased agonist selective for the α7 nicotinic acetylcholine receptor (nAChR), with activation contingent upon the presence of type II positive allosteric modulators, such as PNU120596. It is utilized to investigate neurological disorders and delineate the pharmacological characteristics of the α7nAChR [1].

Simlukafusp alfa (Simridarlimab) is a humanized immunoglobulin antibody that targets the CD274 PD-L1 and CD47 pathways.[1]

(2R,3S)-Emricasan ((2R,3S)-PF 03491390) is an isomer of Emricasan. This compound acts as an orally effective irreversible pan-caspase inhibitor. (2R,3S)-Emricasan inhibits the increase in caspase-3 activity induced by Zika virus (ZIKV) and protects human cortical neural progenitor cells.

Gadopentetic acid (gadolinium complex) (Gd-DTPA) is an paramagnetic contrast agent commonly implemented by a bolus intravenous injection (i.v.) in Dynamic contrast-enhanced MRI (DCE-MRI) studies.

EOB-DTPA is a biochemical reagent that can be synthesized from other compounds and is commonly used in MRI.

Gadoteridol (Gd-HP-DO3A) is a gadolinium-based MRI contrast agent that can be used for central nervous system imaging.

Ethylene thiourea (NCIC03372) is a pesticide used in fruit and vegetable production. Ethylene thiourea is also used as a novel contrast agent for MRI studies based on proton chemical exchange-dependent saturation transfer.

Gadodiamide is an MRI contrast agent, used in MR imaging procedures to assist in the visualization of blood vessels.

Gadobutrol is a nonionic, paramagnetic contrast agent developed for tissue contrast enhancement in magnetic resonance imaging (MRI)

Gadoxetate Disodium is used to evaluate focal liver lesions, such as hepatocellular carcinoma or liver metastasis on T1-weighted imaging. It is a contrast agent in magnetic resonance imaging (MRI) of the hepatobiliary system. It accumulates in normal, fun

Mangafodipir trisodium can enhance contrast in magnetic resonance imaging (MRI) of the liver, is a contrast agent delivered intravenously.

P 569 is an MRI contrast medium.

Sprodiamide is a magnetic susceptibility-based MRI contrast agent.

DOTA-tri(t-butyl ester) is a versatile compound employed for the synthesis of third-generation (G3) nanoglobular magnetic resonance imaging (MRI) contrast agents. These contrast agents find application in the fields of MR angiography and tumor angiogenesis imaging.

(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a potent and selective antagonist of cannabinoid receptor type 1 (CB1R) and inducible nitric oxide synthase (iNOS), with a binding affinity (Ki) of 5.7 nM for CB1R. It holds promise as an investigative tool in liver fibrosis research due to these characteristics.

Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).